Q-omics provides the consensus-scored WNT7B profile across patient tissues and cancer cell-line models. WNT7B expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, WNT7B is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, WNT7B RNA expression shows 14,163 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, HNSC, and TGCT as cancer lineages where WNT7B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for WNT7B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes WNT7B survival associations across molecular data types. WNT7B RNA expression shows survival associations in the most cancer types (25), followed by mutation status (5) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible WNT7B RNA expression–survival associations across cancer types. High WNT7B expression shows unfavorable associations in KIRC, UVM, PAAD and SARC, but favorable associations in LGG and BLCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for WNT7B RNA expression.
This table summarizes WNT7B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for WNT7B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. WNT7B shows lower tumor expression in KIRC and KICH and higher tumor expression in HNSC, COAD, LUSC and BRCA. The HNSC box plot shows higher WNT7B RNA expression in tumor versus normal tissue (log2 FC = +2.424, t-test p < 0.001).
This table shows molecular features associated with WNT7B in patient tissues and cancer cell lines. In patient samples, WNT7B shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, WNT7B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in CNS and LARGE_INTESTINE.
